S-1: Propanc Biopharma Faces Going Concern Doubts Amidst Deep Losses

Propanc Biopharma, a development-stage oncology company, reported substantial net losses and negative cash flows, raising significant doubt about its ability to continue as a going concern, despite recent capital raises.

Summary

• Propanc Biopharma is a development-stage healthcare company focused on new cancer treatments for pancreatic, ovarian, and colorectal cancer, with its lead product candidate, PRP, in preclinical development.
• The company reported a net loss of $4,837,738 for the three months ended September 30, 2025, compared to $354,310 for the same period in 2024, and a net loss of $58,923,300 for the fiscal year ended June 30, 2025, compared to $1,820,528 for the fiscal year ended June 30, 2024.
• As of September 30, 2025, the company had $602,737 in cash and an accumulated deficit of $130,459,258.
• Operating activities used $1,939,067 in cash for the three months ended September 30, 2025, and $405,168 for the fiscal year ended June 30, 2025.
• A public offering in August 2025 raised gross proceeds of $4,000,000, yielding net proceeds of approximately $3,340,000 after deducting underwriting commissions and expenses.
• A private placement with Hexstone Capital LLC in November 2025 generated gross proceeds of approximately $1,000,000 through the issuance of Series C Preferred Stock and a warrant.
• The company's intellectual property portfolio includes 85 granted, allowed, or accepted patents and 5 patent applications related to proenzymes against solid tumors.
• Many convertible notes and loans are past due and in default, with total principal outstanding under various financing agreements being $131,000 for GS Capital notes and $0 for 1800 Diagonal Lending and ONE44 Capital notes as of September 30, 2025, following conversions and repayments.
• Material weaknesses in internal control over financial reporting were identified, including lack of written policies, insufficient segregation of duties, and inadequate monitoring of the financial reporting closing process.
• The company is considered a 'controlled company' under Nasdaq rules, as CEO James Nathanielsz holds a majority of the voting control through Series B Preferred Stock.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, including substantial and increasing net losses, negative cash flow, and a significant accumulated deficit, leading to a 'going concern' qualification. While recent capital raises provide some temporary relief and patent grants are positive, the high level of debt in default, reliance on dilutive financing, and identified material weaknesses in internal controls indicate a very high-risk investment profile with significant operational and financial instability.

Positives

• Successfully completed a public offering in August 2025, raising approximately $3.3 million in net proceeds.
• Secured an additional $1 million in gross proceeds from a private placement with Hexstone Capital LLC in November 2025.
• Received a certificate of grant for a proenzyme composition patent from the USPTO in September 2025, specifically capturing a future clinical dose of PRP.
• Maintains a strong intellectual property portfolio with 90 patents filed in major jurisdictions relating to the use of PRP against solid tumors.
• PRP has been granted Orphan Drug Designation status from the FDA for the treatment of pancreatic cancer, offering developmental incentives.

Negatives

• Reported a significant net loss of $4,837,738 for the three months ended September 30, 2025, a substantial increase from $354,310 in the prior year period.
• Incurred a net loss of $58,923,300 for the fiscal year ended June 30, 2025, a dramatic increase from $1,820,528 in the previous fiscal year.
• Experienced negative cash flows from operations, using $1,939,067 for the three months ended September 30, 2025, and $405,168 for the fiscal year ended June 30, 2025.
• Has an accumulated deficit of $130,459,258 as of September 30, 2025, indicating a history of unprofitability.
• Many loans payable and convertible notes are past due and in default, including the Crown Bridge Note ($65,280 principal, $57,828 accrued interest) and related party loans ($211,545 principal, $31,226 accrued interest) as of September 30, 2025.
• Administration expenses significantly increased to $4,598,574 for the three months ended September 30, 2025, primarily due to stock-based consulting expenses ($3,743,000).
• Research and development expenses decreased due to cost-cutting measures, indicating potential slowdowns in core product development.

Risks

• Substantial doubt about the ability to continue as a going concern due to absence of revenues, recurring losses, and need for additional financing.
• PRP is in early stages of development and may never become commercially viable, leading to potential loss of investment.
• PRP may cause undesirable side effects, impacting clinical trial results, limiting use, and leading to product liability claims.
• Uncertainty in successful product development could materially harm results of operations.
• Clinical trials for PRP could be delayed or unsuccessful due to various factors, including patient enrollment, regulatory requirements, and unforeseen costs.
• Failure to obtain regulatory approval in jurisdictions outside the U.S. would prevent marketing PRP in those regions.
• Inability to establish sales and marketing capabilities or secure third-party agreements could hinder commercialization.
• Substantial competition from major pharmaceutical and biotechnology companies, academic institutions, and research organizations.
• Difficulty in obtaining reimbursement approval for PRP, which could harm business and profitability.
• Geopolitical conflicts, trade restrictions, and tariffs could adversely affect business, financial condition, and results of operations.
• Reliance on substantial debt financing convertible into common stock, which could cause significant dilution and negative price impact.
• Inability to remain in compliance with financial or other covenants in debt instruments could lead to default and adverse effects on business.
• Future sales and issuances of common stock or rights to purchase common stock could result in additional dilution.
• Issuance of additional preferred stock without stockholder approval could make third-party acquisition difficult and depress stock price.
• Limited public market for common stock and potential designation as a 'penny stock' could limit liquidity.
• Volatility in the trading price of common stock due to various factors, including clinical trial results, market conditions, and capital raising efforts.
• Limitations on the ability to use net operating loss carryforwards and certain other tax attributes due to Section 382 of the Internal Revenue Code.
• Material weaknesses in internal control over financial reporting could lead to misstatements or fraud.
• Significant increased costs associated with operating as a public company, including compliance with Sarbanes-Oxley Act and other regulations.
• Judgments obtained against the company may not be enforceable due to substantial assets and some officers/directors being located outside the U.S.
• Control of the company by James Nathanielsz through Series B Preferred Stock limits new investors' ability to elect directors or influence policies.
• Dependence on collaborations with third parties for development and commercialization of PRP, which may be unsuccessful.
• Reliance on single manufacturers for PRP supply creates risks of insufficient quantities or disruptions.

Future Outlook

The company expects to incur significant expenses and increasing operating losses as it progresses PRP into clinical trials, continues R&D, seeks regulatory approvals, establishes sales and marketing infrastructure, expands its intellectual property portfolio, and adds personnel. It anticipates needing substantial additional funding to achieve its business objectives and cannot assure that adequate financing will be available on acceptable terms. The company plans to initiate its Investigational Medicinal Product Dossier, study proposal, and Investigators Brochure, followed by clinical trial application compilation and submission, and then commence a First-In-Human (FIH), Phase Ib study in advanced solid tumor patients, aiming to complete it within twelve months. Further R&D collaborations are under negotiation with the University of Jan and other CROs.

Management Comments

• "We are a development-stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer."
• "Utilizing our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body."
• "Our lead product candidate, PRP, is a variation upon our novel formulation and involves pro-enzymes, the inactive precursors of enzymes."
• "We will not receive any proceeds from the resale of the Shares by the Selling Stockholder in this offering."
• "We expect to incur significant expenses and increasing operating losses for the foreseeable future if and as we progress PRP into clinical trials, continue our R&D, seek regulatory approvals, establish or contract for a sales and marketing infrastructure, maintain and expand our intellectual property portfolio, and add personnel."
• "Management is currently seeking additional funds, primarily through the issuance of equity and/or debt securities for cash to operate our business."
• "The overall decrease in research and development expenses is primarily related to our cost-cutting measures due to lack of working capital funding."

Industry Context

Propanc Biopharma operates in the highly competitive biotechnology and pharmaceutical industries, characterized by continuous technological advancement. The company faces competition from major pharmaceutical and biotechnology companies, academic institutions, and research organizations globally. Its focus on proenzyme-based cancer treatments for solid tumors, particularly pancreatic, ovarian, and colorectal cancers, places it in a niche within oncology. The receipt of Orphan Drug Designation for pancreatic cancer provides a competitive advantage and developmental incentives within that specific rare disease market. However, the industry's high R&D costs, long development timelines, and stringent regulatory hurdles, coupled with the need for significant capital, are substantial challenges for an early-stage company like Propanc. The company's strategy to develop PRP in combination with existing therapies or as a replacement will require overcoming the established market position of current treatments and generic alternatives.

Comparison to Industry Standards

• The company's accumulated deficit of over $130 million and lack of revenue generation are typical for early-stage biopharmaceutical companies, but the magnitude of recent net losses ($58.9 million for FY25) is substantial, indicating high burn rates relative to its stage.
• The reliance on convertible debt with significant discounts and default provisions is a common, yet high-risk, financing method for distressed early-stage biotech firms, often leading to substantial shareholder dilution, which is worse than standard equity financing terms.
• The identification of material weaknesses in internal control over financial reporting is a concern, as robust internal controls are a fundamental standard for public companies, especially those seeking to attract institutional investment.
• The company's intellectual property portfolio of 90 patents is a positive asset, comparable to established development-stage biotech firms, providing a foundation for future commercialization.
• The Orphan Drug Designation for PRP for pancreatic cancer is a positive industry benchmark, as it confers specific benefits and acknowledges the unmet medical need for the target indication, aligning with regulatory incentives for rare disease treatments.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently involved in any litigation that it believes could have a material adverse effect on its financial condition or results of operations.
• The SEC filed a complaint against Crown Bridge in August 2022 due to its violation of Section 15(a)(1) of the Securities Exchange Act of 1934, leading Crown Bridge to surrender all conversion rights in its held convertible notes, including the Crown Bridge Note.

Related Party Transactions

• Lease of principal executive offices from North Horizon Pty Ltd., a related party owned and directed by CEO James Nathanielsz and his wife. The lease was renewed on May 4, 2025, for a one-year term at $3,300 AUD ($2,127 USD) per month plus taxes.
• Total rent payable to North Horizon Pty Ltd. was $112,228 USD ($169,529 AUD) as of September 30, 2025.
• Loans from an institutional investor affiliated with director Josef Zelinger, totaling $120,000 AUD ($78,249 USD) between July 3, 2025, and August 14, 2025, which were fully repaid on August 19, 2025.
• Other loans from Josef Zelinger's affiliated institutional investor, with some past due and in default, totaling $211,545 principal and $31,226 accrued interest as of September 30, 2025.
• Employment agreement with James Nathanielsz (CEO and CFO) with an annual base salary of $600,000 AUD ($414,900 USD) and an annual discretionary bonus up to 100% of his base salary. Accrued unpaid salary and bonus payable to Mr. Nathanielsz and his wife totaled $275,087 USD ($415,540 AUD) as of September 30, 2025.
• Services agreement with Dr. Julian Kenyon (Chief Scientific Officer and director) at an annual salary of $54,000 AUD ($41,580 USD). Accrued salaries for management totaled $142,661 USD ($215,500 AUD) as of September 30, 2025.
• Employee benefit liability of $686,863 as of September 30, 2025, consisting of unpaid or unused annual leave and long service leave for Mr. Nathanielsz and Sylvia Nathanielsz (his wife and part-time employee).

Stakeholder Impact

• **Shareholders:** Significant dilution risk from ongoing convertible debt conversions and future equity raises. The 'going concern' doubt and substantial losses pose a high risk of investment loss. The controlled company status limits influence on corporate governance.
• **Employees:** Management's salary and benefits are substantial relative to the company's financial performance and lack of revenue. Cost-cutting measures have impacted R&D expenses, potentially affecting job security or growth opportunities for scientific staff.
• **Creditors:** Many loans and convertible notes are in default, indicating high credit risk. The company's ability to repay debt is dependent on future capital raises, which may not be on favorable terms.
• **Customers (Future):** The long development timeline and uncertainty of regulatory approval for PRP mean potential customers (patients) will not have access to the product for several years, if ever. Undesirable side effects or lack of efficacy could further delay or prevent market entry.
• **Suppliers/Partners:** Delays in R&D due to funding issues could impact collaboration agreements and manufacturing service agreements, potentially affecting relationships with third-party contractors and research institutions.

Next Steps

• Initiate Investigational Medicinal Product Dossier, study proposal, and Investigators Brochure for PRP.
• Commence study preparation process with contract research organizations (CROs), analytical labs, and trial sites.
• Compile and submit the Clinical Trial Application (CTA) for PRP.
• Begin preparation of logistics and trial site initiation visits.
• Commence a First-In-Human (FIH), Phase Ib study in patients with advanced solid tumors, evaluating safety, pharmacokinetics, and anti-tumor efficacy of PRP, with a goal to complete within twelve months.
• Continue and expand R&D activities, including further collaborations with the University of Jan and other CROs.
• Negotiate with lenders to amend maturity dates for past-due convertible debt.
• Implement and improve managerial, operational, and financial systems to manage anticipated growth.
• Recruit and train additional qualified personnel, particularly in drug development, regulatory affairs, and sales/marketing.
• Establish an audit committee of the board of directors comprised of at least two independent directors.
• Add experienced accounting and financial personnel and retain third-party consultants to review internal controls and recommend improvements.
• Increase the Chief Financial Officer's role from part-time to full-time as the next step in building out the accounting department.

Key Dates

Recommendation

Propanc Biopharma presents an extremely high-risk investment. The company has a history of substantial and increasing net losses, negative cash flow from operations, and a massive accumulated deficit, leading to a 'going concern' qualification from its auditors. Numerous debt instruments are in default, indicating severe financial distress and an inability to meet current obligations. While recent capital raises provide temporary liquidity, they are insufficient to address long-term funding needs without significant further dilution. The lead product candidate, PRP, is still in preclinical development, meaning commercialization is years away and highly uncertain. The identified material weaknesses in internal controls and the controlled company structure further exacerbate governance risks. Given the profound financial instability, high operational risks, and the speculative nature of its product pipeline, the stock carries an exceptionally high risk of capital loss.

Keywords

Biopharma, Cancer Treatment, Oncology, PRP, Proenzymes, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer, Clinical Trials, Orphan Drug Designation, SEC Filing, S-1 Registration, Convertible Debt, Going Concern, Intellectual Property, Biotechnology, Drug Development, Capital Raise, Nasdaq